secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K/A
Filed at:   2022-07-13T23:59:59+00:00
Accession:  0001193125-22-192923
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Graphite Bio reports GPH102 preclinical HDR rates up to 40% in sickle cell HSPCs; IND planned mid-2024
--------------------------------------------------------------------------------

- GPH102 gene replacement achieved homology directed repair (HDR) rates up to 40% in sickle cell HSPCs and restored adult hemoglobin (HbA) expression.
- Company plans to submit an IND for GPH102 in beta-thalassemia by mid-2024, pending regulatory feedback.
- An encore trial-in-progress poster for GPH101 Phase 1/2 CEDAR trial in sickle cell disease was also presented at ASGCT.
- GPH102 uses UltraHDR platform to replace mutated beta-globin gene, targeting >300 mutations that cause beta-thalassemia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000119312522192923/0001193125-22-192923-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000119312522192923/d379068d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-192923

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer